WO 2005/097778 PCT/GB2005/001333

CLAIMS:

1. A compound of formula (I) or a pharmaceutically acceptable salt thereof:

$$R^2$$
 $(R^3)_n$
 (I)

wherein:

5

 R^1 represents $-C_{2-7}$ alkyl or $-(CH_2)_m-C_{3-7}$ cycloalkyl;

R² represents -X-C₃₋₈ cycloalkyl, -X-aryl, -X-heteroaryl, -X-heterocyclyl, -X-C₃₋₈ cycloalkyl-Y-C₃₋₈ cycloalkyl-Y-aryl, -X-C₃₋₈ cycloalkyl-Y-heteroaryl, -X-C₃₋₈ cycloalkyl-Y-heteroaryl, -X-aryl-Y-heterocyclyl, -X-aryl-Y-C₃₋₈ cycloalkyl, -X-aryl-Y-aryl, -X-aryl-Y-heteroaryl-Y-C₃₋₈ cycloalkyl, -X-heteroaryl-Y-aryl, -X-heteroaryl-Y-heteroaryl-Y-heterocyclyl, -X-heterocyclyl-Y-heterocyclyl, -X-heterocyclyl-Y-heterocyclyl, -X-heterocyclyl, such that R² is

15 linked to O via a carbon atom;

W represents a bond, C₁₋₆ alkyl, CO, COC₂₋₆ alkenyl, O or SO₂;

X represents a bond or C₁₋₆ alkyl;

Y represents a bond, C₁₋₆ alkyl, CO, COC₂₋₆ alkenyl, O or SO₂;

Z represents a bond, CO, COC₂₋₆ alkenyl, O or SO₂:

20 R³ represents halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, cyano, amino or trifluoromethyl; m represents an integer from 1-3;

n is 0, 1 or 2;

25

wherein said alkyl groups of R^1 may be optionally substituted by one or more substituents (eg. 1, 2 or 3) which may be the same or different and which are selected from the group consisting of halogen, cyano, =O, C_{1-6} alkyl, C_{1-6} alkoxy, halo C_{1-6} alkyl or halo C_{1-6} alkoxy; wherein said cycloalkyl, aryl, heteroaryl and heterocyclyl groups of R^2 may be optionally substituted by one or more substituents (eg. 1, 2 or 3) which may be the same or different, and which are selected from the group consisting of halogen, hydroxy, cyano, nitro, =O, trifluoromethyl, trifluoromethoxy, fluoromethoxy, difluoromethoxy, C_{1-6} alkyl,

pentafluoroethyl, C₁₋₆ alkoxy, arylC₁₋₆ alkoxy, C₁₋₆ alkylthio, C₁₋₆ alkoxyC₁₋₆ alkyl, C₃₋₇ cycloalkylC₁₋₆ alkoxy, C₁₋₆ alkanoyl, C₁₋₆ alkoxycarbonyl, C₁₋₆ alkylsulfonyl, C₁₋₆ alkylsulfonyloxy, C₁₋₆ alkylsulfonylC₁₋₆ alkylsulfonyloxy, arylsulfonyloxy, arylsulfonylC₁₋₆ alkyl, aryloxy, C₁₋₆ alkylsulfonamido, C₁₋₆ alkylamino, C₁₋₆ alkylamido, -R⁴, -CO₂R⁴, -COR⁴, C₁₋₆ alkylsulfonamidoC₁₋₆ alkyl, C₁₋₆ alkylamidoC₁₋₆ alkyl, arylsulfonamido, arylcarboxamido, arylsulfonamidoC₁₋₆ alkyl, arylcarboxamidoC₁₋₆ alkyl, aroyl, aroylC₁₋₆ alkyl, arylC₁₋₆ alkyl, or a group -NR⁵R⁶, -C₁₋₆ alkyl-NR⁵R⁶, -C₃₋₈ cycloalkyl-NR⁵R⁶, -CONR⁵R⁶,

-NR⁵COR⁶, -NR⁵SO₂R⁶, -OCONR⁵R⁶, -NR⁵CO₂R⁶, -NR⁴CONR⁵R⁶ or -SO₂NR⁵R⁶ (wherein R⁴, R⁵ and R⁶ independently represent hydrogen, C₁₋₆ alkyl, -C₃₋₈ cycloalkyl, -C₁₋₆ alkyl-C₃₋₈ cycloalkyl, aryl, heterocyclyl or heteroaryl or wherein-NR⁵R⁶ may represent a nitrogen

5

15

25

30

35

containing heterocyclyl group, wherein said R^4 , R^5 and R^6 groups may be optionally substituted by one or more substituents (eg. 1, 2 or 3) which may be the same or different, and which are selected from the group consisting of halogen, hydroxy, C_{1-6} alkyl, C_{1-6} alkoxy, cyano, amino, =O or trifluoromethyl); or solvates thereof.

- 2. A compound as defined in claim 1 which is a compound of formula E1-32 or a pharmaceutically acceptable salt thereof.
- A pharmaceutical composition which comprises the compound of formula
 as defined in claim 1 or claim 2 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.
 - 4. A compound as defined in claim 1 or claim 2 for use in therapy.
 - 5. A compound as defined in claim 1 or claim 2 for use in the treatment of neurological diseases.
- 6. Use of a compound as defined in claim 1 or claim 2 in the manufacture of a medicament for the treatment of neurological diseases.
 - 7. A method of treatment of neurological diseases which comprises administering to a host in need thereof an effective amount of a compound of formula (I) as defined in claim 1 or claim 2 or a pharmaceutically acceptable salt thereof.
 - 8. A pharmaceutical composition for use in the treatment of neurological diseases which comprises the compound of formula (I) as defined in claim 1 or claim 2 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
 - 9. A process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof, which process comprises:
 - (a) reacting a compound of formula (II)

$$H \stackrel{O}{\longrightarrow} N - R^1$$
(II)

wherein R^1 , R^3 and n are as defined in claim 1, with a compound of formula R^{2^i} - L^1 , wherein R^{2^i} is as defined in claim 1 for R^2 or a group convertible thereto and L^1 represents a suitable

WO 2005/097778

leaving group such as a halogen atom (eg. bromine or iodine) or an optionally activated hydroxyl group;

(b) reacting a compound of formula (III)

$$R^2$$
 $(R^3)_n$
 $N-H$

5

wherein R², R³ and n are as defined in claim 1, with a compound of formula R¹-L², wherein R¹ is as defined in claim 1 for R¹ or a group convertible thereto and L² represents a suitable leaving group such as a halogen atom (eg. bromine, iodine or tosylate); or

10

- (c) reacting a compound of formula (III) as defined above, with a ketone of formula $R^{1"}=0$, wherein $R^{1"}$ is $=C_{2-7}$ alkyl or $=(CH_2)_m-C_{3-7}$ cycloalkyl or a group convertible thereto; or
- (d) deprotecting a compound of formula (I) which is protected; or

15

(e) interconversion from one compound of formula (I) to another.